Albumin administration in the acutely ill: what is new and where next?

Jean-Louis Vincent, James A Russell, Matthias Jacob, Greg Martin, Bertrand Guidet, Jan Wernerman, Ricard Ferrer, Stuart A McCluskey, Luciano Gattinoni, Jean-Louis Vincent, James A Russell, Matthias Jacob, Greg Martin, Bertrand Guidet, Jan Wernerman, Ricard Ferrer, Stuart A McCluskey, Luciano Gattinoni

Abstract

Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients.

Figures

Figure 1
Figure 1
Schematic illustration of metabolism of albumin in healthy adults. GI, gastrointestinal.
Figure 2
Figure 2
Schematic illustration of the current understanding of vascular barrier function within the high-pressure segment of the vascular system. For explanation, see text. White arrows, hydrostatic pressure (HP) gradients towards the interstitial space; thick black arrow, inward directed oncotic force across the endothelial surface layer; thin black arrow, small flux of protein low ultrafiltrate. EC, endothelial cell; EG, endothelial glycocalyx; ESL, endothelial surface layer; IS, interstitial space; PF, protein free space beneath the endothelial surface layer; RC, red blood cell; VL, vascular lumen.
Figure 3
Figure 3
Some of the key substances transported by albumin. NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug.

References

    1. Ancell H. Course of lectures on the physiology and pathology of the blood, and other animal fluids. Lancet. 1839;33:222–231.
    1. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ. 1998;317:235–240. doi: 10.1136/bmj.317.7153.235.
    1. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol. 2009;23:183–191. doi: 10.1016/j.bpa.2008.11.004.
    1. Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, Norton R. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333:1044.
    1. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003;237:319–334.
    1. Laxenaire MC, Charpentier C, Feldman L. Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim. 1994;13:301–310. doi: 10.1016/S0750-7658(94)80038-3.
    1. McClelland DB. Safety of human albumin as a constituent of biologic therapeutic products. Transfusion. 1998;38:690–699. doi: 10.1046/j.1537-2995.1998.38798346639.x.
    1. American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004;170:1247–1259.
    1. Peters T. All About Albumin. San Diego: Academic Press; 1995.
    1. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012;33:209–290. doi: 10.1016/j.mam.2011.12.002.
    1. The Bovine and Human Albumin Programs. [ ]
    1. Matejtschuk P, Dash CH, Gascoigne EW. Production of human albumin solution: a continually developing colloid. Br J Anaesth. 2000;85:887–895. doi: 10.1093/bja/85.6.887.
    1. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599–610. doi: 10.1093/bja/85.4.599.
    1. Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, Calman KC. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985;1:781–784.
    1. Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia. 1998;53:789–803. doi: 10.1046/j.1365-2044.1998.00438.x.
    1. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384–394. doi: 10.1093/bja/aer515.
    1. Jacob M, Bruegger D, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, Becker BF. The endothelial glycocalyx affords compatibility of Starling's principle and high cardiac interstitial albumin levels. Cardiovasc Res. 2007;73:575–586. doi: 10.1016/j.cardiores.2006.11.021.
    1. Adamson RH, Lenz JF, Zhang X, Adamson GN, Weinbaum S, Curry FE. Oncotic pressures opposing filtration across non-fenestrated rat microvessels. J Physiol. 2004;557:889–907. doi: 10.1113/jphysiol.2003.058255.
    1. Jacob M, Bruegger D, Rehm M, Welsch U, Conzen P, Becker BF. Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology. 2006;104:1223–1231. doi: 10.1097/00000542-200606000-00018.
    1. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000;440:653–666. doi: 10.1007/s004240000307.
    1. Zausig YA, Chappell D, Becker BF, Potschka D, Busse H, Nixdorf K, Bitzinger D, Jacob B, Jacob M. The impact of crystalloidal and colloidal infusion preparations on coronary vascular integrity, interstitial oedema and cardiac performance in isolated hearts. Crit Care. 2013;17:R203. doi: 10.1186/cc12898.
    1. Chappell D, Westphal M, Jacob M. The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness. Curr Opin Anaesthesiol. 2009;22:155–162. doi: 10.1097/ACO.0b013e328328d1b6.
    1. Jacob M, Chappell D. Reappraising Starling: the physiology of the microcirculation. Curr Opin Crit Care. 2013;19:282–289. doi: 10.1097/MCC.0b013e3283632d5e.
    1. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783–1787. doi: 10.1016/j.febslet.2008.04.057.
    1. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol. 2007;151:580–590. doi: 10.1038/sj.bjp.0707251.
    1. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. Ann Intensive Care. 2013;3:4. doi: 10.1186/2110-5820-3-4.
    1. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99–110. doi: 10.2165/11539220-000000000-00000.
    1. Figge J, Rossing TH, Fencl V. The role of serum proteins in acid–base equilibria. J Lab Clin Med. 1991;117:453–467.
    1. Jorgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb Res. 1980;17:13–18. doi: 10.1016/0049-3848(80)90289-3.
    1. Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, Brimioulle S, Appoloni O, Creteur J, Vincent JL. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34:2536–2540. doi: 10.1097/01.CCM.0000239119.57544.0C.
    1. Redelmeier DA. New thinking about postoperative hypoalbuminemia: a hypothesis of occult protein-losing enteropathy. Open Med. 2009;3:e215–e219.
    1. Caironi P, Gattinoni L. The clinical use of albumin: the point of view of a specialist in intensive care. Blood Transfus. 2009;7:259–267.
    1. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987;79:1635–1641. doi: 10.1172/JCI113000.
    1. Barle H, Hammarqvist F, Westman B, Klaude M, Rooyackers O, Garlick PJ, Wernerman J. Synthesis rates of total liver protein and albumin are both increased in patients with an acute inflammatory response. Clin Sci (Lond) 2006;110:93–99. doi: 10.1042/CS20050222.
    1. Serra R, Caroleo S, Buffone G, Lugara M, Molinari V, Tropea F, Amantea B, de Franciscis S. Low serum albumin level as an independent risk factor for the onset of pressure ulcers in intensive care unit patients. Int Wound J. 2012. doi: 10.1111/iwj.12004.
    1. Al-Subaie N, Reynolds T, Myers A, Sunderland R, Rhodes A, Grounds RM, Hall GM. C-reactive protein as a predictor of outcome after discharge from the intensive care: a prospective observational study. Br J Anaesth. 2010;105:318–325. doi: 10.1093/bja/aeq171.
    1. Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med. 2010;36:1657–1665. doi: 10.1007/s00134-010-1928-z.
    1. Lee EH, Baek SH, Chin JH, Choi DK, Son HJ, Kim WJ, Hahm KD, Sim JY, Choi IC. Preoperative hypoalbuminemia is a major risk factor for acute kidney injury following off-pump coronary artery bypass surgery. Intensive Care Med. 2012;38:1478–1486. doi: 10.1007/s00134-012-2599-8.
    1. Lyons O, Whelan B, Bennett K, O'Riordan D, Silke B. Serum albumin as an outcome predictor in hospital emergency medical admissions. Eur J Intern Med. 2010;21:17–20. doi: 10.1016/j.ejim.2009.10.010.
    1. Bernard F, Al-Tamimi YZ, Chatfield D, Lynch AG, Matta BF, Menon DK. Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment. J Trauma. 2008;64:872–875. doi: 10.1097/TA.0b013e31803428cc.
    1. Namendys-Silva SA, Gonzalez-Herrera MO, Texcocano-Becerra J, Herrera-Gomez A. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 2011;28:253–257. doi: 10.1177/1049909110384841.
    1. de la Cruz KI, Bakaeen FG, Wang XL, Huh J, LeMaire SA, Coselli JS, Chu D. Hypoalbuminemia and long-term survival after coronary artery bypass: a propensity score analysis. Ann Thorac Surg. 2011;91:671–675. doi: 10.1016/j.athoracsur.2010.09.004.
    1. Artero A, Zaragoza R, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care. 2010;25:276–281. doi: 10.1016/j.jcrc.2009.12.004.
    1. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8:e59321. doi: 10.1371/journal.pone.0059321.
    1. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134:36–42. doi: 10.1001/archsurg.134.1.36.
    1. Skillman JJ, Restall DS, Salzman EW. Randomized trial of albumin vs. electrolyte solutions during abdominal aortic operations. Surgery. 1975;78:291–303.
    1. Roberts I, Edwards P, McLelland B. More on albumin. Use of human albumin in UK fell substantially when systematic review was published. BMJ. 1999;318:1214–1215.
    1. CSM Expert Working Party. The safety of human albumin. Curr Probl Pharmacovigilance. 1999;25:11.
    1. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256.
    1. Woodruff LM, Gibson ST. The clinical evaluation of human albumin. US Naval Med Bull. 1942;40:791–796.
    1. Dear Doctor Letter – Albumin Use in Seriously Ill Patients. [ ]
    1. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409. doi: 10.1056/NEJM199908053410603.
    1. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149–164. doi: 10.7326/0003-4819-135-3-200108070-00007.
    1. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37:86–96.
    1. Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, Kai LS, Vallance S. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357:874–884.
    1. Safety of Albumin Administration in Critically Ill Patients. [ ]
    1. Vincent JL, Sakr Y, Reinhart K, Sprung CL, Gerlach H, Ranieri VM. Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. Crit Care. 2005;9:R745–R754. doi: 10.1186/cc3895.
    1. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med. 2011;39:386–391. doi: 10.1097/CCM.0b013e3181ffe217.
    1. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med. 2012;38:368–383. doi: 10.1007/s00134-012-2472-9.
    1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637. doi: 10.1097/CCM.0b013e31827e83af.
    1. Charpentier J, Mira JP. EARSS Study Group. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study [abstract] Intensive Care Med. 2011;37(Suppl 2):S115–0438.
    1. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412–1421. doi: 10.1056/NEJMoa1305727.
    1. Cooper DJ, Myburgh J, Heritier S, Finfer S, Bellomo R, Billot L, Murray L, Vallance S. Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality? J Neurotrauma. 2013;30:512–518. doi: 10.1089/neu.2012.2573.
    1. Van Aken HK, Kampmeier TG, Ertmer C, Westphal M. Fluid resuscitation in patients with traumatic brain injury: what is a SAFE approach? Curr Opin Anaesthesiol. 2012;25:563–565. doi: 10.1097/ACO.0b013e3283572274.
    1. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;30:2175–2182. doi: 10.1097/00003246-200210000-00001.
    1. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33:1681–1687. doi: 10.1097/01.CCM.0000171539.47006.02.
    1. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999;30:639–645. doi: 10.1016/S0168-8278(99)80194-9.
    1. Doungngern T, Huckleberry Y, Bloom JW, Erstad B. Effect of albumin on diuretic response to furosemide in patients with hypoalbuminemia. Am J Crit Care. 2012;21:280–286. doi: 10.4037/ajcc2012999.
    1. Guevara M, Terra C, Nazar A, Sola E, Fernandez J, Pavesi M, Arroyo V, Gines P. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012;57:759–765. doi: 10.1016/j.jhep.2012.06.013.
    1. Kwok CS, Krupa L, Mahtani A, Kaye D, Rushbrook SM, Phillips MG, Gelson W. Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int. 2013;2013:295153.
    1. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, Terra C, Fabrega E, Arroyo V, Rodes J, Gines P. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–1359. doi: 10.1053/j.gastro.2008.02.024.
    1. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830–835. doi: 10.1007/s10620-007-9919-9.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Wiedermann CJ, Joannidis M. Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med. 2014;40:160–170. doi: 10.1007/s00134-013-3156-9.
    1. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP. et al.Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367:124–134. doi: 10.1056/NEJMoa1204242.
    1. Rehm M, Orth V, Kreimeier U, Thiel M, Haller M, Brechtelsbauer H, Finsterer U. Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy. Anesthesiology. 2000;92:657–664. doi: 10.1097/00000542-200003000-00008.
    1. Jacob M, Chappell D, Hofmann-Kiefer K, Helfen T, Schuelke A, Jacob B, Burges A, Conzen P, Rehm M. The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humans. Crit Care. 2012;16:R86. doi: 10.1186/cc11344.
    1. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012;308:1566–1572. doi: 10.1001/jama.2012.13356.
    1. Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med. 1999;27:46–50. doi: 10.1097/00003246-199901000-00025.
    1. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transfus Med Rev. 2010;24:53–63. doi: 10.1016/j.tmrv.2009.09.005.
    1. Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2005;33:1638–1641. doi: 10.1097/01.CCM.0000169876.14858.91.
    1. Martin GS. Pharmacological aspects of albumin as a niche product in the intensive care unit. Crit Care Med. 2005;33:1667–1669. doi: 10.1097/.
    1. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin – serious adverse events reported worldwide in 1998–2000. Br J Anaesth. 2003;91:625–630. doi: 10.1093/bja/aeg233.
    1. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg. 2004;139:552–563. doi: 10.1001/archsurg.139.5.552.
    1. Groeneveld AB, Navickis RJ, Wilkes MM. Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg. 2011;253:470–483. doi: 10.1097/SLA.0b013e318202ff00.
    1. Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care. 2007;22:197–203. doi: 10.1016/j.jcrc.2006.11.005.
    1. Farrugia A, Bansal M, Balboni S, Kimber MC, Martin GS, Cassar J. Choice of fluids in severe septic patients – a cost-effectiveness analysis informed by recent clinical trials. Rev Recent Clin Trials. 2013. [Epub ahead of print]
    1. Vincent JL, Fink MP, Marini JJ, Pinsky MR, Sibbald WJ, Singer M, Suter PM, Cook D, Pepe PE, Evans T. Intensive care and emergency medicine: progress over the past 25 years. Chest. 2006;129:1061–1067. doi: 10.1378/chest.129.4.1061.
    1. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する